• 1
    Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 22530.
  • 2
    Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 173541.
  • 3
    Metha N, Azfar R, Shin D. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research database. Eur Heart J 2010; 31: 10006.
  • 4
    Davidovici B, Sattar N, Prinz JC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 178596.
  • 5
    Strange A, Capon F, Spencer CC et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP 1. Nat Genet 2010; 42: 98590.
  • 6
    Stuart PE, Nair RP, Ellinghaus E et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010; 42: 10004.
  • 7
    Ellinghaus E, Ellinghaus D, Stuart PE et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42: 9915.
  • 8
    Kathiresan S, Voight BF, Purcell S et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Gen 2009; 41: 33441.
  • 9
    Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol 2008; 298: 3218.
  • 10
    Neimann AI, Shin DB, Wang X. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 82955.
  • 11
    Wolk K, Mallbris L, Larsson P et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 4927.
  • 12
    Mejer K, deVries M, Al-Lahham S et al. Human primary adipocytes exhibit immune cell function; adipocytes prime inflammation independent of macrophages. PLoS ONE 2011; 6: e17154.
  • 13
    Hansson Gk, Libby P. The immune response in atherosclerosis: a double edge sword. Nat Rev Immunol 2006; 6: 50819.
  • 14
    Liu Z, Wang L, Lu F. Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. J Mol Cell Biol 2012; doi 10.1007//s00011-012-0510-2. [Epub ahead of print].
  • 15
    Prodanovich S, Ma F, Taylor JR. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 2627.
  • 16
    Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 12138.
  • 17
    Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011; 63: 5229.
  • 18
    Greenberg JD, Kremer JM, Curtis JR et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum 2011; 70: 57682.
  • 19
    Ryan C, Leonardi C, Kueger JG. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA 2011; 306: 86471.
  • 20
    Ahlehoff O, Skov L, Gislason G et al. cardiovascular event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2012; doi: 10.1111/j.1365-2796.2012.02593.x. [Epub ahead of print].